Tobramycin Pediatric Dose — Antimicrobial Dosing Guide
Tobramycin is an aminoglycoside antibiotic that exerts bactericidal activity by irreversibly binding the 30S ribosomal subunit, inhibiting bacterial protein synthesis. It is active against a broad range of gram-negative organisms, including Pseudomonas aeruginosa, and is commonly used in pediatric patients for serious gram-negative infections and as a cornerstone agent in cystic fibrosis (CF) pulmonary exacerbations. Weight-based dosing varies significantly by age group and clinical indication.
Pediatric Dosing
| Patient Population | Dose | Frequency |
|---|---|---|
| Term Infants <1 month | 2.5 mg/kg/dose IV | Every 8 hours |
| Children >1 month (standard) | 5–7.5 mg/kg/day IV | Every 24 hours |
| Cystic Fibrosis (>1 month) | 10 mg/kg/dose IV | Every 24 hours |
Maximum dose: 500 mg/day, except in cystic fibrosis patients, for whom higher cumulative daily doses may be required per institutional CF protocol.
Worked examples: For a 4 kg term neonate: 4 × 2.5 mg/kg = 10 mg/dose IV every 8 hours. For a 20 kg child (>1 month, non-CF): 20 × 5 mg/kg = 100 mg/day IV every 24 hours (up to 20 × 7.5 = 150 mg/day). For a 30 kg CF patient: 30 × 10 mg/kg = 300 mg/dose IV every 24 hours.
Indications and Clinical Context
Tobramycin is indicated for serious gram-negative bacterial infections in pediatric patients, including bacteremia, pneumonia, urinary tract infections, and healthcare-associated infections caused by susceptible organisms such as Pseudomonas aeruginosa, Escherichia coli, and Klebsiella species. Extended-interval (once-daily) dosing in children over 1 month leverages the concentration-dependent killing pharmacodynamics of aminoglycosides and is associated with comparable efficacy and a potentially favorable nephrotoxicity profile compared with traditional multiple-daily dosing.
In cystic fibrosis, higher doses of 10 mg/kg/day IV are employed to overcome altered pharmacokinetics, including increased volume of distribution and accelerated drug clearance characteristic of CF patients. This indication warrants close collaboration with a CF care team and therapeutic drug monitoring protocols.
Administration and Monitoring
Tobramycin is administered intravenously, typically infused over 30–60 minutes. In neonates (<1 month), every-8-hour dosing reflects the immature renal clearance in this population; renal function should be assessed prior to initiation and monitored throughout the course. For patients >1 month receiving once-daily dosing, peak and trough serum concentrations should be obtained and interpreted according to institutional therapeutic drug monitoring guidelines to optimize efficacy and minimize toxicity.
- Nephrotoxicity: Monitor serum creatinine and urine output; avoid concurrent nephrotoxic agents where possible.
- Ototoxicity: Cumulative exposure may cause auditory or vestibular toxicity; baseline and periodic audiologic assessment is recommended with prolonged courses.
- Max dose: 500 mg/day in standard patients; consult institutional protocol for CF patients where this cap does not apply.
- Renal dosing adjustment: Dose interval and/or dose reduction are required in patients with renal impairment; consult institutional protocol.
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.